Gonadotropin-releasing hormone antagonist in uterine adenomyosis: some light at the end of the tunnel

other OA: green public-domain-us
AI-generated summary by claude@2026-08, 2026-08-01

This review explores the potential of gonadotropin-releasing hormone antagonists for treating uterine adenomyosis, offering promising therapeutic avenues.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-21 · read from full text

The paper discusses gonadotropin-releasing hormone (GnRH) antagonist therapy in uterine adenomyosis, focusing on the rationale and reported outcomes associated with this treatment approach. It presents adenomyosis as the target condition and summarizes the context in which GnRH antagonists have been used, with emphasis on what benefits have been observed. A key limitation is that the article is a brief, commentary-style piece rather than a detailed primary clinical trial report with fully specified methods and results. This paper is centrally about adenomyosis — it focuses on GnRH antagonist treatment for uterine adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 602 characters · extracted from oa-html · click to expand
Gonadotropin-releasing hormone antagonist in uterine adenomyosis: some light at the end of the tunnel. (2025) Fertility and sterility — Vol. 3, n° 454, p. 455 (2025) (2025) Fertility and sterility — Vol. 3, n° 454, p. 455 (2025) Open Access - Adobe PDF - 65.34 KB - Authors - Author Donnez, Jacques - Author - Affiliations - APA - Chicago - FWB Donnez, J., & Dolmans, M.-M. (2025). Gonadotropin-releasing hormone antagonist in uterine adenomyosis: some light at the end of the tunnel. Fertility and sterility, 3(454), 455. https://doi.org/10.1016/j.fertnstert.2025.06.013 (Original work published 2025)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-08-11T06:11:44.160905+00:00
pubmed
last seen: 2026-08-11T06:08:31.010751+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine